ArticleAmerican journal of physiology. Endocrinology and metabolism2024
Maternal GLP-1 receptor activation inhibits fetal growth.
Article in American journal of physiology. Endocrinology and metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 16 citations in OpenAlex.
- Targeting metabolism to protect fertility and healthy pregnancy with SGLT2 inhibitors and GLP-1RAs.Current opinion in physiology · 2026Article
- Postpartum GLP-1 receptor agonists and SGLT-2 therapies in women with prior gestational diabetes: current evidence and uncertainties.BMC medicine · 2026Review
- Maternal obesity and the metabolic syndrome in reproductive health: assessing incretin-based interventions.Reviews in endocrine & metabolic disorders · 2026Review
- Periconceptional use of GLP-1 receptor agonists and the risk of major congenital malformations: a systematic review and meta-analysis.Endocrine connections · 2026Article
- Perinatal Semaglutide Treatment Improves Maternal Health and Mitigates Offspring Metabolic Dysfunction in a Mouse Model of Maternal Obesity.bioRxiv : the preprint server for biology · 2026Article
- Balancing the benefits and risks of GLP-1 receptor agonists: a clinical guide for shared decision-making.EClinicalMedicine · 2026Review
- Maternal Nutrition and Hypothalamic Programming of Offspring Metabolic Health.The Journal of nutrition · 2026Review
- Semaglutide Induces Oxidative Stress and Differentially Modulates mTOR-Dependent Growth and Invasion in Human Trophoblast Cell Models: Implications for Placental Function.Current issues in molecular biology · 2026Article
- GLP-1 Receptor Agonist Use Across Preconception, Pregnancy, and the Postpartum Periods.Paediatric drugs · 2026Review
- GLP-1 Receptor Agonists, Fertility Restoration, and Reproductive Safety in Women of Reproductive Age: A Narrative Review.Journal of clinical medicine · 2026Review
- Impact of semaglutide pretreatment on reproductive outcomes in women with overweight and obesity with infertility: a real-world multicenter cohort study.Reproductive biology and endocrinology : RB&E · 2026Article
- Pharmacological Management of Obesity in Pregnancy: A Review of Current and Emerging Therapies.Drugs · 2026Review
- Unintentional periconceptional exposure to glucagon-like peptide-1 receptor agonists and adverse pregnancy outcomes: A nationwide cohort study in Taiwan.Diabetes, obesity & metabolism · 2026Article
- Effects of semaglutide on vessel morphology: Studies on the chicken chorioallantoic membrane.Microvascular research · 2026Article
- Neuroendocrine crosstalk between sex and metabolic hormones: mechanisms and implications across the female reproductive spectrum.Discover endocrinology and metabolism · 2026Review
- Obesity Medications Beyond Glucose Control and Weight Reduction: Updates on the Expanding Benefits, Clinical Challenges, and Future Directions.Current hypertension reports · 2025Review
- Incretin receptor agonism during pregnancy: implications for mother and baby.Clinical science (London, England : 1979) · 2025Review
- GLP-1-Mediated Pregnancy and Neonatal Complications in Mice.Journal of developmental biology · 2025Article
- Maternal plasma extracellular vesicles tsRNA as potential biomarkers for assessing preterm labor risk.BMC pregnancy and childbirth · 2025Article
- Considering the use of GLP-1 receptor agonists in women with obesity prior to pregnancy: a narrative review.Archives of gynecology and obstetrics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Glucagon-like peptide 1 (GLP-1) regulates food intake, insulin production, and metabolism. Our recent study demonstrated that pancreatic α-cells-secreted (intraislet) GLP-1 effectively promotes maternal insulin secretion and metabolic adaptation during pregnancy. However, the role of circulating GLP-1 in maternal energy metabolism remains largely unknown. Our study aims to investigate systemic GLP-1 response to pregnancy and its regulatory effect on fetal growth. Using C57BL/6 mice, we observed a gradual decline in maternal blood GLP-1 concentrations. Subsequent administration of the GLP-1 receptor agonist semaglutide (Sem) to dams in late pregnancy revealed a modest decrease in maternal food intake during initial treatment. At the same time, no significant alterations were observed in maternal body weight or fat mass. Notably, Sem-treated dams exhibited a significant decrease in fetal body weight, which persisted even following the restoration of maternal blood glucose levels. Despite no observable change in placental weight, a marked reduction in the placenta labyrinth area from Sem-treated dams was evident. Our investigation further demonstrated a substantial decrease in the expression levels of various pivotal nutrient transporters within the placenta, including glucose transporter one and sodium-neutral amino acid transporter one, after Sem treatment. In addition, Sem injection led to a notable reduction in the capillary area, number, and surface densities within the labyrinth. These findings underscore the crucial role of modulating circulating GLP-1 levels in maternal adaptation, emphasizing the inhibitory effects of excessive GLP-1 receptor activation on both placental development and fetal growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.